Clinical trial NCT06862908: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Subjects With HFpEF（Heart Failure With Preserved ejectIon Fraction）or HFmrEF（Heart Failure With Mildly Reduced Ejection Fraction）Combined With Obesity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Obesity
Heart Failure With Preserved Ejection Fraction (HFPEF)
Heart Failure With Mildly Reduced Ejection Fraction
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2025-03-06
Enrollment: 141
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in Chinese subjects with heart failure with ejection fraction retention/mild ejection fraction reduction (HFpEF/HFmrEF) combined with obesity (BMI≥28kg/㎡). This study will enroll about 141 NYHA Class II-III HFpEF/HFmrEF subjects combined with obesity. Eligible participants will be randomly assigned to IBI362 4 mg, IBI362 6 mg, or placebo at a ratio of 1:1:1, randomized by concomitant atrial fibrillation during screening (history/screening ECG).

The trial period includes a 2-week screening period, a 52-week double-blind treatment period, and a 4-week safety follow-up period.


Eligibility criteria: Inclusion criteria:

1. Age ≥18 at the time of signing the informed consent.
2. BMI≥28kg/m2.
3. NYHA Grade II-III.
4. There were no hospitalizations due to heart failure at screening visit (V1) to randomized visit (V2).
5. KCCQ-CSS score \< 80 during the screening period and before randomization.
6. Medication for underlying diseases: If used before screening, the dose should be stable for ≥4 weeks; If not used before screening, the drug should also be stopped for ≥4 weeks.
7. The fertile subject agrees to use the contraceptive method prescribed in this protocol for the entire study period and for 3 months after the final treatment. Pregnancy test results for fertile women during the screening period must be negative. Female subjects should not breastfeed.
8. Voluntarily sign the informed consent form, and be willing to strictly abide by the requirements and restrictions of the informed consent form and the protocol throughout the study period, including but not limited to: maintaining a stable diet and exercise lifestyle, injecting the study drugs as planned, and keeping a study diary.

Exclusion criteria:

1. Myocardial infarction, stroke, hospitalization for heart failure, unstable angina pectoris, or transient ischemic attack (TIA) in the 3 months prior to screening.
2. Hospitalization for acute heart failure or use of any respiratory and circulatory AIDS (such as intraaortic balloon counterpulsation (IABP)/interventional artificial heart (IMPELLA)/extracorporeal membrane oxygenation (ECMO)/continuous kidney replacement therapy (CRRT)) within 3 months before screening.
3. Poorly controlled hypertension at the screening stage, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg. Or systolic blood pressure \< 90mmHg during screening.
4. Had previously undergone or planned to undergo bariatric surgery during the study period.
5. The presence of endocrine diseases or medical history that may significantly affect body weight.
6. Previous diagnosis of type 1 diabetes or specific type diabetes.
7. Use of GLP-1R agonists or glucagon receptor (GLP-1R/GCGR) agonists or GIPR (Glucagon dependent insulinotropic polypeptide) within 3 months before screening receptor) /GLP-1R agonist or GIPR/GLP-1R/GCGR agonist; Participants who stopped using these drugs more than 3 months prior to screening due to lack of efficacy or intolerance should also be excluded.
8. Use of insulin in the 3 months prior to screening to control diabetes, except for short-term (cumulative ≤14 days) use of insulin in acute conditions, such as acute illness, hospitalization, or elective surgery. The last insulin treatment was less than 14 days from the screening date.
9. History of medullary thyroid carcinoma, multiple endocrine neoplasia (MEN) 2A or 2B or family history.
10. Clinically significant gastric empting abnormalities (such as severe diabetic gastroparesis, gastric pyloric obstruction, etc.) or gastrointestinal surgery.
11. Active or untreated malignancies were present within 5 years prior to screening, or clinical malignancies were in remission (except in subjects with no recurrence after surgery for basal cell and squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the prostate, or papillary thyroid carcinoma).
12. A history of atopic reactions (clinical manifestations of severe or multiple allergies) or a history of clinically significant multiple or severe drug allergies, or intolerance to local glucocorticoids, Or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme, linear immunoglobulin A dermatitis, toxic epidermal necrolysis, anaphylaxis, angioedema, or exfoliative dermatitis).
13. History of organ transplantation (except corneal transplantation, autologous skin transplantation), or preparing to receive organ transplantation.
14. The investigators identified major surgeries that might be planned during the study period that would affect the participants' ability to walk.
15. Past suicidal thoughts or behaviors.
16. The investigator believes that the subjects are not suitable to participate in the study because of any other factors (including previous serious mental illness) that may affect the efficacy, safety evaluation or compliance of the study.

Primary outcomes:
measure: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
timeFrame: From baseline (week 0) to week 36
measure: Body weight change from baseline at week 36
timeFrame: From baseline (week 0) to week 36
Secondary outcomes:
measure: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Body weight change from baseline at week 52
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Incidence, severity, and association with study drugs of adverse events
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Change in Systolic Blood Pressure (SBP)
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Change in Diastolic Blood Pressure(DBP)
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Change in ECG heart rate
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Change in N terminal pro B type natriuretic peptide（NT-proBNP）
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Change in hypersensitive C-reactive protein（hsCRP）
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Occurrence of serum anti-iBI362 antibody (ADA) before and after administration
timeFrame: From baseliFrom baseline (week 0) to end of treatment (week 52)ne (week 0) to week 52
measure: Occurrence of neutralizing antibody (NAb) before and after administration
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: Pharmacokinetics (PK): Maximum Concentration (Cmax) of IBI362
timeFrame: From baseline (week 0) to end of treatment (week 52)
measure: PK: Area Under the Concentration Versus Time Curve (AUC) of IBI362
timeFrame: From baseline (week 0) to end of treatment (week 52)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital, CAMS&PUMC
state: Beijing
Study officials:
References: